Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
I-MAB ( (IMAB) ) has shared an update.
I-Mab has announced a strategic portfolio prioritization, focusing on the development of givastomig, a bispecific antibody targeting CLDN18.2-positive tumor cells in first-line metastatic gastric cancers, with additional potential in other solid tumors. This decision follows encouraging early data and aims to accelerate the drug’s development, supported by a solid financial position expected to sustain operations into 2027. The company has also paused the development of uliledlimab to concentrate resources on givastomig, highlighting its commitment to advancing its lead clinical program.
More about I-MAB
I-Mab is a U.S.-based global biotechnology company that focuses on the development of precision immuno-oncology agents for cancer treatment. With operations established in Rockville, Maryland, and Short Hills, New Jersey, I-Mab aims to advance innovative therapies in the field of oncology.
YTD Price Performance: 3.19%
Average Trading Volume: 422,994
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $72.39M
For an in-depth examination of IMAB stock, go to TipRanks’ Stock Analysis page.
